Brief: Tenax Therapeutics Provides Update On Tnx-102, Tnx-103 And Tnx-201 Clinical Programs
04/01/2022 14:36
Jan 4 (Reuters) - Tenax Therapeutics Inc TENX.O :
* TENAX THERAPEUTICS PROVIDES UPDATE ON TNX-102, TNX-103 AND
TNX-201 CLINICAL PROGRAMS
* TENAX THERAPEUTICS INC - PLANS TO INITIATE PHASE 3 STUDY
OF
TNX-201 (ORAL IMATINIB MESYLATE) IN PULMONARY ARTERIAL
HYPERTENSION IN 2H 2022
* TENAX THERAPEUTICS INC - RECEIVES A NOTICE OF ALLOWANCE OF
MULTIPLE PATENT CLAIMS FOR TNX-102 (SUBCUTANEOUS LEVOSIMENDAN)
* TENAX THERAPEUTICS INC - SUCCESSFULLY COMPLETES IV TO ORAL
TRANSITION SUBSTUDY FOR TNX-103 (ORAL LEVOSIMENDAN)
Source text for Eikon: ID:nGNX4PlJ8H
Further company coverage: TENX.O
((Reuters.Briefs@thomsonreuters.com;))